Essilor International (EPA:EI) stock price target increased to 115.00EUR, released a report earlier today by Societe Generale
- Updated: November 29, 2016
Only yesterday Essilor International (EPA:EI) traded 0.00% even at 99.99EUR. Essilor International’s 50-day average is 0.00EUR and its two hundred day average is 0.00EUR. With the last stock price close up 0.00% from the 200-day moving average, compared to the Standard & Poor's 500 Index which has decreased -0.03% over the same time. 0 shares of EI traded, down from an avg. volume of 0
Indicating a possible upside of 0.15%, Societe Generale bumped up the target of Essilor International (EPA:EI) to 115.00EUR
Previously on 11/27/2016, UBS AG reported on Essilor International (EPA:EI) upped the target price from 0.00EUR to 130.00EUR. At the time, this indicated a possible upside of 0.31%.
Essilor International has a one year low of 0.00EUR and a one year high of 0.00EUR The company’s market cap is currently 0 EUR.
General Information About Essilor International (EPA:EI)
Essilor International SA, formerly Essilor International Compagnie Generale D'Optique SA, is an ophthalmic optics company. The Company designs, manufactures and markets a range of lenses to improve and protect eyesight. It also develops and markets equipment for prescription laboratories, and instruments and services for eye care professionals. It operates through three segments: Lenses and Optical Instruments, Equipment, and Sunglasses & Readers. It is a North American provider of non-prescription reading glasses. It also sells non-prescription sunglasses. It has approximately 32 plants, over 490 prescription laboratories, edging facilities and local distribution centers, and over five research and development centers across the world. The Company designs, manufactures and customizes corrective lenses. The Company provides a range of lenses for correcting myopia, hyperopia, astigmatism and presbyopia. It operates through MyOptique Group.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.